ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Service Firm Evotec Acquires DeveloGen

by Michael McCoy
July 19, 2010 | APPEARED IN VOLUME 88, ISSUE 29

Evotec, a drug discovery and contract research firm, has agreed to acquire DeveloGen, a developer of small-molecule drugs based in Göttingen, Germany. Evotec will pay about $18 million and make future performance-related payments. Formed in 1997, DeveloGen has alliances with Boehringer Ingelheim on small-molecule diabetes treatments and with Andromeda Biotech on a synthetic peptide for diabetes. Evotec CEO Werner Lanthaler says the purchase adds to the firm’s list of high-value partnerships.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment